07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Symplmed sales and marketing update

Symplmed launched Prestalia perindopril/amlodipine tablets in the U.S. to treat hypertension. The initial recommended dose is 2.5 amlodipine/3.5 perindopril mg once daily for one to two weeks and then reassessing to see if more or...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

Prestalia perindopril/amlodipine regulatory update

FDA approved Prestalia perindopril/amlodipine from Symplmed to treat hypertension. Symplmed plans to launch the drug this quarter. Symplmed has exclusive, U.S. rights to the fixed-dose combination of perindopril arginine, an angiotensin-converting enzyme (ACE) inhibitor, plus...
02:28 , Jan 27, 2015 |  BC Extra  |  Company News

FDA approves Symplmed's Prestalia combo for hypertension

Symplmed Pharmaceuticals LLC (Cincinnati, Ohio) said FDA approved an NDA for Prestalia to treat hypertension. The company plans to launch the fixed-dose combination of perindopril arginine plus amlodipine besylate this quarter through its bpCareConnect program,...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Symplmed, Xoma deal

Symplmed acquired from Xoma exclusive, U.S. rights to develop and commercialize a fixed-dose combination of perindopril/amlodipine and a sublicense to promote Aceon perindopril erbumine in the U.S. Xoma will receive an undisclosed equity stake in...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Coveram perindopril/amlopidine: Phase III data

Top-line data from the double-blind, U.S. Phase III PATH trial in 837 patients showed that once-daily oral Coveram produced significantly greater reductions in both seated DBP and SBP from baseline to week 6 compared to...
07:00 , Oct 15, 2012 |  BioCentury  |  Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Teva, Krka d.d., Lupin, Mylan, Servier, Alliance Healthcare (Distribution) Ltd. cardiovascular news

The European Commission sent a statement of objections to Servier and the generic competitors regarding an investigation into suspected violations of EU antitrust laws relating to Servier's cardiovascular drug Coversyl perindopril. The EC alleged that...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

Perindopril/amlodipine: Phase III started

In late February, Xoma began the double-blind, U.S. Phase III PATH trial to compare an oral fixed-dose combination of perindopril plus amlodipine once daily for 6 weeks vs. perindopril or amlodipine alone in about 816...
08:00 , Nov 7, 2011 |  BioCentury  |  Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to...